Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 3/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2144707 | 0.87 | CRBN (0.44) | ALDH1A1KDM4EHPGDCRBNHSD17B3 | |
| SCHEMBL18586593 | 0.81 | CRBN (0.45) | ALDH1A1KDM4EHPGDCRBNMEN1 | |
| SCHEMBL2145067 | 0.78 | NR1H2 (0.54) | ALDH1A1KDM4EHPGDCRBNHSD17B3 | |
| SCHEMBL14876263 | 0.76 | KDM4E (0.67) | ALDH1A1KDM4EHPGDCRBNCASP1 | |
| SCHEMBL2065531 | 0.75 | KDM4E (0.57) | ALDH1A1KDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL29606824 | 0.75 | KDM4E (0.57) | ALDH1A1KDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL2144236 | 0.75 | CA9 (0.46) | ALDH1A1CASP1MEN1KMT2AGAA | |
| SCHEMBL2144223 | 0.75 | CA9 (0.46) | ALDH1A1CASP1MEN1KMT2AGAA | |
| SCHEMBL5307734 | 0.74 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDCRBNCASP1 | |
| Hydrochloric Acid SCHEMBL11289267 | 0.74 | KDM4E (0.55) | ALDH1A1KDM4EHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | ALDH1A1 1694/4885KDM4E 1965/4885HPGD 1179/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | ALDH1A1 1694/4885KDM4E 1965/4885HPGD 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.